NASDAQ:CFMS - ConforMIS Stock Price, News & Analysis

$1.92
-0.10 (-4.95 %)
(As of 08/25/2019 01:55 PM ET)
Today's Range
$1.8550
Now: $1.92
$2.06
50-Day Range
$1.51
MA: $2.56
$3.89
52-Week Range
$0.36
Now: $1.92
$4.83
Volume800,564 shs
Average Volume1.22 million shs
Market Capitalization$131.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$89.79 million
Book Value$0.40 per share

Profitability

Net Income$-43,370,000.00

Miscellaneous

Employees262
Market Cap$131.87 million
Next Earnings Date10/30/2019 (Estimated)
OptionableNot Optionable

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.


ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

How were ConforMIS's earnings last quarter?

ConforMIS Inc (NASDAQ:CFMS) posted its quarterly earnings data on Wednesday, July, 31st. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.01. The medical instruments supplier earned $19.59 million during the quarter, compared to the consensus estimate of $19.36 million. ConforMIS had a negative net margin of 34.68% and a negative return on equity of 92.18%. View ConforMIS's Earnings History.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for ConforMIS.

What price target have analysts set for CFMS?

4 Wall Street analysts have issued 12-month target prices for ConforMIS's stock. Their forecasts range from $2.50 to $4.00. On average, they expect ConforMIS's stock price to reach $3.1250 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View Analyst Price Targets for ConforMIS.

What is the consensus analysts' recommendation for ConforMIS?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS.

What are Wall Street analysts saying about ConforMIS stock?

Here are some recent quotes from research analysts about ConforMIS stock:
  • 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (8/5/2019)
  • 2. BTIG Research analysts commented, "$3 PT on Improving Trends We maintain our Buy rating and $3 PT following 1Q19 results which came in slightly ahead of expectations. Revenue of $20.6M compared favorably to BTIG/Street estimates of $20.0M/$20.1M. Noticeably CFMS saw encouraging uptake with both iTotal PS (+29% xFx) and iTotal Hip (still in the early stages of launch). GMs continued their upward trajectory, increasing 290 bps Y/Y to 47.6%. We believe CFMS’s worst days are behind it and the company is entering into a phase of improved and steady LSD growth driven by existing and recently launched products which give a growing distributor base a full recon line to sell. Recon surgery is clearly moving rapidly towards robotics but CFMS is going against the grain with an alternative option that may appeal to a group of surgeons who don’t want to be tied to a robotic system." (5/2/2019)

Has ConforMIS been receiving favorable news coverage?

News articles about CFMS stock have trended positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ConforMIS earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for ConforMIS.

Who are some of ConforMIS's key competitors?

What other stocks do shareholders of ConforMIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Cisco Systems (CSCO), Alibaba Group (BABA), Advanced Micro Devices (AMD), Intel (INTC), Trevena (TRVN), AbbVie (ABBV) and Pfizer (PFE).

Who are ConforMIS's key executives?

ConforMIS's management team includes the folowing people:
  • Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
  • Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
  • Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
  • Mr. Ed Kilgallen, VP of Operations
  • Ms. Lisa M. Donnelly, Sr. VP of Global Marketing

When did ConforMIS IPO?

(CFMS) raised $135 million in an IPO on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are ConforMIS's major shareholders?

ConforMIS's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (7.76%), BlackRock Inc. (6.12%), Vanguard Group Inc. (4.37%), ARK Investment Management LLC (0.65%), Wells Fargo & Company MN (0.54%) and Jane Street Group LLC (0.31%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Patricia A Davis, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.

Which institutional investors are selling ConforMIS stock?

CFMS stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, Joseph P. Lucia & Associates LLC, Creative Planning, HighTower Advisors LLC, Morgan Stanley, Larson Financial Group LLC and Marathon Capital Management. Company insiders that have sold ConforMIS company stock in the last year include Archon Capital Management Llc, Bradley Langdale, Mark A Augusti, Patricia A Davis and Paul S Weiner. View Insider Buying and Selling for ConforMIS.

Which institutional investors are buying ConforMIS stock?

CFMS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., ARK Investment Management LLC, Bank of New York Mellon Corp, Chicago Equity Partners LLC, Jane Street Group LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for ConforMIS.

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $1.92.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $131.87 million and generates $89.79 million in revenue each year. The medical instruments supplier earns $-43,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. ConforMIS employs 262 workers across the globe.View Additional Information About ConforMIS.

What is ConforMIS's official website?

The official website for ConforMIS is http://www.conformis.com/.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]


MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Featured Article: What is Call Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel